Title |
Genetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis
|
---|---|
Published in |
BMC Cancer, October 2013
|
DOI | 10.1186/1471-2407-13-479 |
Pubmed ID | |
Authors |
Wen-guo Jiang, Xin-an Lu, Bo-yang Shang, Yan Fu, Sheng-hua Zhang, Daifu Zhou, Liang Li, Yi Li, Yongzhang Luo, Yong-su Zhen |
Abstract |
Endostatin (ES) inhibits endothelial cell proliferation, migration, invasion, and tube formation. It also shows antiangiogenesis and antitumor activities in several animal models. Endostatin specifically targets tumor vasculature to block tumor growth. Lidamycin (LDM), which consists of an active enediyne chromophore (AE) and a non-covalently bound apo-protein (LDP), is a member of chromoprotein family of antitumor antibiotics with extremely potent cytotoxicity to cancer cells. Therefore, we reasoned that endostatin-lidamycin (ES-LDM) fusion proteins upon energizing with enediyne chromophore may obtain the combined capability targeting tumor vasculature and tumor cell by respective ES and LDM moiety. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Kenya | 1 | 33% |
Unknown | 2 | 67% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 67% |
Scientists | 1 | 33% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 17 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 5 | 29% |
Student > Master | 3 | 18% |
Researcher | 2 | 12% |
Student > Bachelor | 1 | 6% |
Unspecified | 1 | 6% |
Other | 2 | 12% |
Unknown | 3 | 18% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 7 | 41% |
Biochemistry, Genetics and Molecular Biology | 2 | 12% |
Agricultural and Biological Sciences | 2 | 12% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 6% |
Unspecified | 1 | 6% |
Other | 0 | 0% |
Unknown | 4 | 24% |